Profile
QLGN VRTX ALNY REGN ARGX SGEN
Company Name Qualigen Therapeutics, Inc. Vertex Pharmaceuticals Incorporated Alnylam Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc. argenx SE Seagen Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $3.54M $101.65B $61.42B $57.97B $46.27B $43.15B
Employees 0.00K 6.10K 2.23K 15.16K 1.60K 3.26K
CEO Kevin A. Richardson II Reshma Kewalramani FASN, Yvonne L. Greenstreet Leonard S. Schleifer Timothy Van Hauwermeiren EMBA, David R. Epstein
Ratings
QLGN VRTX ALNY REGN ARGX SGEN
Quant Rating Score 2 4 1 4 4 3
Quant Rating Sell Buy Strong Sell Buy Buy Neutral
Trading
QLGN VRTX ALNY REGN ARGX SGEN
Last Close $2.0001 $391.36 $461.24 $575.06 $752.32 $228.74
High 52 $5.08 $516.74 $482.13 $1150.19 $768 $228.74
Low 52 $0.1 $366.54 $224.58 $482.92 $519.76 $228.74
Price vs. 52 Week High -60.63 % -24.26 % -4.33 % -50 % -2.04 % 0 %
Price vs. 52 Week Low 1900.1 % 6.77 % 105.38 % 19.08 % 44.74 % 0 %
Total Return
QLGN VRTX ALNY REGN ARGX SGEN
1 Month Return 5.27 % -0.36 % 2.75 % -0.92 % 15.06 % 0 %
3 Month Return -43.02 % -11.46 % 49.37 % 12.99 % 39.14 % 0 %
6 Month Return -35.48 % -23.82 % 82.16 % -15.15 % 22.49 % 0 %
9 Month Return -52.72 % -16.6 % 87.05 % -22.29 % 17.86 % 0 %
YTD Return -52.49 % -2.82 % 96.01 % -19.27 % 22.33 % 0 %
1 Year Return 1025.55 % -18.68 % 68.05 % -49.85 % 44.06 % 0 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
QLGN VRTX ALNY REGN ARGX SGEN
Dividend Yield Percentage (TTM) - - - 0.47 % - -
Dividend Paid and Capex Coverage Ration (TTM) -75.76 % 11.09 % -0.43 % 4.37 % -44.32 % -5.87 %
Dividend Per Share (TTM) - - - 2.64 % - -
Payout Ratio (TTM) -1.28 % - - 4.18 % - -
Profitability
QLGN VRTX ALNY REGN ARGX SGEN
Gross Profit Margin TTM 44.48 % 86.11 % 83.64 % 81.98 % 65.32 % 79.1 %
Return on Assets TTM -176.18 % 15.13 % -6.99 % 11.67 % 15.06 % -16.61 %
Return on Equity TTM 2583.42 % 22.14 % -274.21 % 15.11 % 18.96 % -20.8 %
Return on Capital Employed TTM 424.27 % 19.72 % -5.52 % 11.45 % 5.04 % -21.46 %
Net Income Per EBT TTM 100.05 % 83.16 % 84.06 % 91.46 % 237.3 % 101.33 %
EBT Per Ebit TTM 99.54 % 111.48 % 210.66 % 123.23 % 147.38 % 98.26 %
EBIT Per Revenue TTM -313.32 % 34.36 % -7.32 % 27.83 % 13.47 % -31.24 %
Cash Flow To Debt Ratio TTM -186.82 % 251.83 % -1.2 % 175.35 % -175.92 % -1043.73 %
Receivables Turnover TTM 0.68 6.03 4.34 2.53 1.91 3.91
Payables Turnover TTM 0.09 0.43 3.93 3.54 0.88 1.97
Inventory Turnover TTM - 1.06 5.62 0.8 2.21 0.96
Fixed Asset Turnover TTM - 431.08 % 355.68 % 293.64 % 5009.77 % 665.41 %
Asset Turnover TTM 56.46 % 47.51 % 53.92 % 37.19 % 31.97 % 53.41 %
Operating Cash Flow Per Share TTM -4.01 14.98 -0.12 45.13 -1.07 -2.46
Free Cash Flow Per Share TTM -4.01 13.63 -0.4 36.58 -1.09 -2.88
Cash Per Share TTM 19.69 % 3036 % 2203.63 % 7107.14 % 5536.58 % 939.52 %
Operating Cash Flow Sales Ratio TTM -302.01 % 33.68 % -0.63 % 33.37 % -3.31 % -23.12 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 90.99 % 335.21 % 81.05 % 102.26 % 117.04 %
Cash Flow Coverage Ratios TTM -186.82 % 251.83 % -1.2 % 175.35 % -175.92 % -1043.73 %
Price To Free Cash Flows Ratio TTM -0.52 29.05 -1179.18 15.08 -596.18 -81.26
Price To Operating Cash Flows Ratio TTM -0.52 26.46 -3910.39 12.33 -706.75 -93.1
Price Cash Flow Ratio TTM -0.52 26.46 -3910.39 12.33 -706.75 -93.1
Income Statement (TTM)
QLGN VRTX ALNY REGN ARGX SGEN
Revenue $0B $11.02B $2.25B $14.2B $2.19B $1.96B
Gross Profit $0B $9.49B $1.92B $11.75B $1.96B $1.55B
Gross Profit Ratio 0% 86.11% 85.62% 82.74% 89.62% 79.1%
EBITDA $-0.01B $0.49B $-0.18B $5.32B $0.11B $-0.62B
Net Income $-0.01B $-0.54B $-0.28B $4.41B $0.83B $-0.61B
EPS Diluted -17.28 -2.08 -2.16 38.34 12.78 -3.3
Balance Sheet (MRQ)
QLGN VRTX ALNY REGN ARGX SGEN
Long Term Debt $0B $1.66B $1.25B $2.7B $0.03B $0.04B
Total Liabilities $0B $6.12B $4.17B $8.41B $0.7B $0.87B
Total Equity $0B $16.41B $0.07B $29.35B $5.5B $2.8B
Total Investments $0B $6.65B $1.73B $15.42B $1.93B $1.42B
Total Debt $0B $1.75B $1.3B $2.7B $0.04B $0.04B
Total Assets $0B $22.53B $4.24B $37.76B $6.2B $3.67B
Cash Flow Statement (TTM)
QLGN VRTX ALNY REGN ARGX SGEN
Net Income $-0.01B $-0.54B $-0.28B $4.41B $0.83B $-0.61B
Inventory $0B $-0.52B $0.01B $-0.62B $-0.1B $-0.23B
Dividends Paid $-0B $0B $0B $0B $0B $0B
Operating Cash Flow $-0.01B $-0.49B $-0.01B $4.42B $-0.08B $-0.45B
Capital Expenditure $0B $-0.3B $-0.03B $-0.76B $-0.07B $-0.08B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 39.2
AARD Aardvark Therapeutics, Inc. Common Stock 10.99
ABCL AbCellera Biologics Inc. 4.565
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.635
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 1.255
ABPWW 0.046281
ABSI Absci Corporation 2.555
ABUS Arbutus Biopharma Corporation 4.425
ABVC ABVC BioPharma, Inc. 2.8645
ABVX Abivax SA American Depositary Shares 81.05
ACAD ACADIA Pharmaceuticals Inc. 24.2
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.7602
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 2.965
ACIU AC Immune SA 2.46
ETFs With Exposure to QLGN
Ticker ETF Name Weight Percentage Price
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 143.9
VXF Vanguard Extended Market Index Fund 0 209.23
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 158.72
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 158.73
VEMPX Vanguard Extended Market Index InstlPlus 0 391.7
Unlock